

Table 2. Summary of Natural History Study Mechanistic Samples for Participants over Baseline & Follow-up (Complete Collection/Visit Hx Required*). Subjects that Develop T1D at some point during P2 or P3 are Excluded.
 P2 (n=1052); P3:6m (n=498); P3:12m (n=275); P3:18m (n=179) P3:24m (n=100); P3:30m (n=53); P3:36m (n=22)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing	Total No. Subjects Submitting Sample (%)
Baseline	DNA	273 (45.7)	98 (16.4)	209 (35.0)	17 (2.8)	597 (56.7)
	HLA	498 (48.4)	157 (15.3)	334 (32.5)	39 (3.8)	1028 (97.7)
	RNA	221 (46.4)	82 (17.2)	159 (33.4)	14 (2.9)	476 (45.2)
	PLASMA	216 (46.8)	79 (17.1)	154 (33.3)	13 (2.8)	462 (43.9)
	SERUM	217 (46.6)	80 (17.2)	155 (33.3)	14 (3.0)	466 (44.3)
	PBMC	213 (46.3)	81 (17.6)	153 (33.3)	13 (2.8)	460 (43.7)
Follow-up (6m)	RNA	125 (49.6)	39 (15.5)	82 (32.5)	6 (2.4)	252 (50.6)
	PLASMA	120 (48.8)	39 (15.9)	81 (32.9)	6 (2.4)	246 (49.4)
	SERUM	122 (49.2)	39 (15.7)	81 (32.7)	6 (2.4)	248 (49.8)
	PBMC	120 (48.8)	39 (15.9)	81 (32.9)	6 (2.4)	246 (49.4)
Follow-up (12m)	RNA	69 (43.4)	27 (17.0)	59 (37.1)	4 (2.5)	159 (57.8)
	PLASMA	68 (43.3)	27 (17.2)	58 (36.9)	4 (2.5)	157 (57.1)
	SERUM	68 (43.6)	27 (17.3)	57 (36.5)	4 (2.6)	156 (56.7)
	PBMC	70 (43.8)	27 (16.9)	59 (36.9)	4 (2.5)	160 (58.2)
Follow-up (18m)	RNA	55 (45.5)	16 (13.2)	47 (38.8)	3 (2.5)	121 (67.6)
	PLASMA	55 (46.6)	16 (13.6)	44 (37.3)	3 (2.5)	118 (65.9)
	SERUM	54 (45.8)	16 (13.6)	45 (38.1)	3 (2.5)	118 (65.9)
	PBMC	55 (45.8)	16 (13.3)	46 (38.3)	3 (2.5)	120 (67.0)
Follow-up (24m)	RNA	33 (41.3)	11 (13.8)	34 (42.5)	2 (2.5)	80 (80.0)
	PLASMA	33 (41.3)	11 (13.8)	34 (42.5)	2 (2.5)	80 (80.0)
	SERUM	33 (41.3)	11 (13.8)	34 (42.5)	2 (2.5)	80 (80.0)
	PBMC	33 (41.3)	11 (13.8)	34 (42.5)	2 (2.5)	80 (80.0)
Follow-up (30m)	RNA	21 (46.7)	6 (13.3)	16 (35.6)	2 (4.4)	45 (84.9)
	PLASMA	22 (47.8)	6 (13.0)	16 (34.8)	2 (4.3)	46 (86.8)
	SERUM	22 (47.8)	6 (13.0)	16 (34.8)	2 (4.3)	46 (86.8)
	PBMC	22 (47.8)	6 (13.0)	16 (34.8)	2 (4.3)	46 (86.8)
Follow-up (36m)	RNA	10 (50.0)	2 (10.0)	7 (35.0)	1 (5.0)	20 (90.9)
	PLASMA	10 (50.0)	2 (10.0)	7 (35.0)	1 (5.0)	20 (90.9)
	SERUM	10 (50.0)	2 (10.0)	7 (35.0)	1 (5.0)	20 (90.9)
	PBMC	10 (50.0)	2 (10.0)	7 (35.0)	1 (5.0)	20 (90.9)

* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, as well as have completed "all" P3 visits preceding their latest P3 visit.

** All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.